Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DGP Induction Chemotherapy in Stage III NSCLC
NCT00003037Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 1997
- Primary completion
- Mar 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started Apr 1997; status: completed.
02
Drugs
docetaxelgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003037.